The stock price of Pacific Biosciences of California Inc (NASDAQ: PACB) has jumped by 7.67 compared to previous close of 1.76. Despite this, the company has seen a gain of 7.06% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
Moreover, the 36-month beta value for PACB is 1.94. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for PACB is 262.20M and currently, short sellers hold a 19.88% of that float. On November 29, 2024, PACB’s average trading volume was 9.52M shares.
PACB’s Market Performance
The stock of Pacific Biosciences of California Inc (PACB) has seen a 7.06% increase in the past week, with a -12.27% drop in the past month, and a 38.32% gain in the past quarter. The volatility ratio for the week is 7.73%, and the volatility levels for the past 30 days are at 13.72% for PACB. The simple moving average for the past 20 days is -7.22% for PACB’s stock, with a -16.09% simple moving average for the past 200 days.
Analysts’ Opinion of PACB
Jefferies, on the other hand, stated in their research note that they expect to see PACB reach a price target of $4. The rating they have provided for PACB stocks is “Buy” according to the report published on June 03rd, 2024.
PACB Trading at -0.54% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.21% of loss for the given period.
Volatility was left at 13.72%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares sank -11.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.13% lower at present.
During the last 5 trading sessions, PACB rose by +8.19%, which changed the moving average for the period of 200-days by -70.54% in comparison to the 20-day moving average, which settled at $2.0435. In addition, Pacific Biosciences of California Inc saw -80.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Kim Susan G., who sale 19,782 shares at the price of $1.72 back on Sep 30 ’24. After this action, Kim Susan G. now owns 695,654 shares of Pacific Biosciences of California Inc, valued at $34,065 using the latest closing price.
SUSAN KIM, the Officer of Pacific Biosciences of California Inc, proposed sale 19,782 shares at $1.72 during a trade that took place back on Sep 30 ’24, which means that SUSAN KIM is holding shares at $34,061 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -2.15 for the present operating margin
- 0.18 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.28. The total capital return value is set at -0.27. Equity return is now at value -64.80, with -23.55 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 1.97. The interest coverage ratio of the stock is -26.21.
Currently, EBITDA for the company is -277.28 million with net debt to EBITDA at -2.63. When we switch over and look at the enterprise to sales, we see a ratio of 7.91. The receivables turnover for the company is 5.89for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.74.
Conclusion
To wrap up, the performance of Pacific Biosciences of California Inc (PACB) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
